Secondary metabolites of plants have been proposed as sources of multiple benefits in different fields. Flavonoids are a subtype of them with medicinal effects as anti-viral/bacterial, anti-inflammatory, cardioprotective, anti-diabetic, among others. However, characteristics such as bioavailability (BA) and pharmacokinetic (PK) behavior have become challenging in their biological response. For that reason, pharmaceutical science proposes strategies that can improve their responses. The aim of this review is to introduce the flavonoid drug delivery systems (FDDSs) by oral route that have been patented in the period of 2011-2023 years through the systematic screening of patent filings, using the Espacenet database of the European Patent Office (EPO). As a result of that, 29 patents were included in the final review. Flavonoids reported as quercetin, myricetin, rutin were both botanical-derived and synthetic substances. According to the findings, dosage forms such as tablets, pellets, pills, microparticles, polymeric micelles, and liposomes ameliorate the BA and PK properties in the biological response of the flavonoids. The patents also showed different trends in manufacturing processes that use innovative strategies as well as optimization of critical variables. The carrier associations with different polymers were also mentioned. Based on all the above, it was possible to conclude that the pharmaceutical trending in flavonoids dosage forms included a wide scope of formulations for oral use, incorporating some polymers that can control the release mechanism. This document allowed to know the innovative treatment strategies based on flavonoids for different health problems.